12/30/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – telitromycin

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Telitromycin

Telitromycin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Källén B, Danielsson BR. Fetal safety of erythromycin An update of Swedish data. Eur J Clin Pharmacol. 2014;70:355-60.

  2. Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368(0):m331.

  3. Keskin-Arslan E, Erol H, Uysal N, Karadas B, Temiz T, Kaplan YC. Pregnancy outcomes following maternal macrolide use: A systematic review and meta-analysis. Reprod Toxicol. 2023;115:124-146.

  4. Andersson NW, Olsen RH, Andersen JT. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021;372(0):n107.

  5. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.

  6. Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053-62.

  7. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 1999;13:531-6.

  8. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24:1241-8.

  1. Källén B, Danielsson BR. Fetal safety of erythromycin An update of Swedish data. Eur J Clin Pharmacol. 2014;70:355-60.
  2. Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368(0):m331.
  3. Keskin-Arslan E, Erol H, Uysal N, Karadas B, Temiz T, Kaplan YC. Pregnancy outcomes following maternal macrolide use: A systematic review and meta-analysis. Reprod Toxicol. 2023;115:124-146.
  4. Andersson NW, Olsen RH, Andersen JT. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. BMJ. 2021;372(0):n107.
  5. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648e1-648e15.
  6. Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053-62.
  7. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 1999;13:531-6.
  8. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf. 2015;24:1241-8.